Cargando…
Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy
Triple-negative breast cancers (TNBCs) are aggressive forms of breast cancer and tend to grow and spread more quickly than most other types of breast cancer. TNBCs can neither be targeted by hormonal therapies nor the antibody trastuzumab that targets the HER2 protein. There are urgent unmet medical...
Autores principales: | Dong, Shengli, Matossian, Margarite D., Yousefi, Hassan, Khosla, Maninder, Collins-Burow, Bridgette M., Burow, Matthew E., Alahari, Suresh K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363135/ https://www.ncbi.nlm.nih.gov/pubmed/37481672 http://dx.doi.org/10.1038/s41598-023-37058-4 |
Ejemplares similares
-
Ceritinib is a novel triple negative breast cancer therapeutic agent
por: Dong, Shengli, et al.
Publicado: (2022) -
Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment
por: Nguyen, Khoa, et al.
Publicado: (2021) -
Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model
por: Matossian, Margarite D., et al.
Publicado: (2018) -
Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes
por: Matossian, Margarite D., et al.
Publicado: (2017) -
Constitutive activation of MEK5 promotes a mesenchymal and migratory cell
phenotype in triple negative breast cancer
por: Matossian, Margarite D., et al.
Publicado: (2021)